top of page
VENTRIPOINT and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND’s Gen3Echo™ platform
Toronto, Ontario – December 18, 2024 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce Ventripoint and ASCEND Cardiovascular, a leading provider of cardiovascular IT solutions, have signed a term sheet defining the general terms and conditions for a non-exclusive license to Ventripoint’s VMS+ proprietary technology. The two parties expect to execute the license agreement within 30 days. ASCEND Cardiovascular has ov
May 224 min read
Archives
bottom of page

